Figure 4. Individual subject Tinnitus Functional Index (TFI) baseline and 6 months post Widex Zen Therapy scores for the 24 subjects. The solid line represents equivalent baseline vs final (post treatment) scores while the dashed line represents the 13-point benefit score required for clinical efforts to be considered clinically significant.

Clinical Trial on the Effectiveness of Widex Zen Therapy for Tinnitus

The results from this clinical study strongly support the use of Widex Zen Therapy in tinnitus patient management. This individualized comprehensive approach combining counseling (instructional and adjustment-based cognitive behavioral intervention), amplification, fractal tones and/or noise, and relaxation strategies was highly effective in reducing tinnitus handicap in a short period of time, with improvements apparent through at least the 6-month duration of this investigation.

Tinnitus

First-Ever Clinical Practice Guideline for Tinnitus Published by AAO-HNSF

The AAO-HNS guideline gives healthcare providers a framework for care and support in mitigating the personal and social impact that tinnitus can have. The recommendation includes obtaining a comprehensive audiologic examination and recommendation of sound therapy for patients with persistent bothersome tinnitus.

The MADSEN Astera2 features a dedicated tinnitus assessment module designed to help clinicians address increased claims for tinnitus and hearing loss disability.

Tinnitus Assessment: The Key to Successful Tinnitus Management

The Hearing Review asks three audiologists associated with GN Otometrics and Audiology Systems—Clément Sanchez, AuD, Wendy Switalski, AuD, and Clint Keifer, AuD—for their thoughts on the benefits of tinnitus assessment. They also provide advice to hearing care professionals who are interested in adding tinnitus assessment to their practice.

ear ringing

Issues in Tinnitus: 2014-2015

A look at what the most recent scientific literature says about tinnitus treatment, as well as a review of Cognitive Behavioral Therapy (CBT), Progressive Tinnitus Management (PTM), and Tinnitus Retraining Therapy (TRT).

logo auris_medical_2f

Auris Medical Holding AG Announces Launch and Pricing of IPO

Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company’s common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.